Jan 27 2010
Eribis Pharmaceuticals AB - part of
the Karolinska Development portfolio - announced today that it has received
follow-on financial investment enabling the company to continue its clinical
development program. Based on cardio-protective effects, Eribis' candidate
drug has the potential to become an important new therapy for treating acute
coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when
blood supply returns after a period of ischemia), as well as for surgical
preconditioning. The new round of investment from Karolinska Development AB
will allow Eribis to strengthen the preclinical material.
In studies to date, Eribis' novel peptide therapy has shown excellent
Cardio-protective effects in conditions of ACS and reperfusion. Potential
benefits of the candidate drug include a decrease in the amount of cardiac
tissue damage, an extension of the window of time available for treatment of
ischemic conditions and a reduction of cardiovascular complications such as
heart failure.
Eribis Pharmaceutical's CEO, Herman Krapf, said, "We are delighted that
Karolinska Development continues to show confidence in our development
program. This latest round of financing comes after strong preclinical
results and means we can now move forward towards the clinical program.
Successful development offers significant market potential as there is an
urgent need for new and improved therapies in the area of cardio-protection."
SOURCE Eribis Pharmaceuticals AB